

REMARKS

The purpose of this paper is to amend the specification to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

Drawings

In the Office Action mailed November 6, 2007, Figure 1 is objected to for allegedly reciting biological sequences. The biological sequences in the objected figure have been disclosed in the sequence listing page. Withdrawal of the objection is respectfully requested.

Sequence disclosure

A sequence disclosure which complies with the requirements set forth under §1.821(c) is enclosed herewith, rendering the objection thereof moot.

Specification

The specification has been amended to recite sequence identifier numbers of the biological sequences recited therein. No new matter is added.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Anthony J. Zelano, Reg. No. 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: HERTIN-0001
Date: June 6, 2008